New Build Report: Pharmaceutical-Biotech Sector Plans 198 New North American Facilities with $21 Billion in Capital Investment Potential
New Build Report: Pharmaceutical-Biotech Sector Plans 198 New North American Facilities with $21 Billion in Capital Investment Potential
Attachment: Life-Science Industry
SUGAR LAND--August 11, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The Pharmaceutical-Biotech Industry has 198 reported new facility builds in the works throughout North America, according to Industrial Info's Pharmaceutical-Biotech Online Database. Collectively, the sites have 220 reported projects, representing a total reported capital investment of $21 billion, which translates to a per-site average of about $105.5 million.
Within this article: Details on some of the most anticipated Pharmaceutical-Biotech Industry projects in North America, including those from leading companies such as Ajinomoto Althea Incorporated, LFB USA, Novo Nordisk (NYSE:NVO) and Novavax (NASDAQ:NVAX).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- COVID-19 Underscores Need for Drug Manufacturing to Return to U.S. Shores
- U.S. Mid-Atlantic Region Sees Strong Life Science Capital Construction Acti...
- Join Industrial Info for a Webinar on the Pharmaceutical-Biotech Industry
- Industrial Info's Disaster Impact Tracker Monitors Path of Hurricane Floren...
- Industrial Info to Present Webinar on Global Pharmaceutical-Biotech Project...